GlassScriptPhysician profile
James A Turbett
NPI 1730156621
$2,959.10
in general payments reported to CMS, 2019-2025
24 companies · $760 in 2025
The $760 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $68.87 · 2021: $141 · 2022: $281 · 2023: $641 · 2024: $865 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $439.87 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $326.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $308.53 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $270.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $268.24 | 2019-2025 | |
| Amgen INC. | $230.29 | 2020-2025 | Evenity, Prolia |
| Exact Sciences Corporation | $196.99 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $189.21 | 2023-2025 | Ubrelvy |
| Inspire Medical Systems, INC. | $140.64 | 2021 | |
| Glaxosmithkline, LLC. | $89.95 | 2022-2024 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $65.56 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $63.07 | 2024-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $60.98 | 2023-2025 | Veozah, Myrbetriq |
| Revance Therapeutics, INC. | $54.08 | 2024 | Daxxify |
| Merck Sharp & Dohme LLC | $50.87 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $47.10 | 2019-2020 | |
| Dynavax Technologies Corporation | $34.35 | 2023 | Heplisav-B |
| Hologic Sales and Service, LLC | $24.06 | 2025 | Aptima |
| Mannkind Corporation | $22.85 | 2025 | |
| Allergan, INC. | $17.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.91 | 2022 | |
| Sanofi Pasteur INC. | $17.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Turbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.